Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance

References

• Andey T, Sudhakar G, Marepally S, et al. (2015). Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation. Mol Pharm 12:1105–20
   PubMed Web of Science ®Google Scholar
• Cho HJ, Yoon HY, Koo H, et al. (2011). Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials 32:7181–90
   PubMed Web of Science ®Google Scholar
• Coleman RL, Monk BJ, Sood AK, et al. (2013). Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10:211–24
   PubMed Web of Science ®Google Scholar
• Ghosh SC, Neslihan Alpay S, Klostergaard J. (2012). CD44: a validated target for improved delivery of cancer therapeutics. Expert Opin Ther Targets 16:635–50
   PubMed Web of Science ®Google Scholar
• Hadinoto K, Sundaresan A, Cheow WS. (2013). Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm 85:427–43
   PubMed Web of Science ®Google Scholar
• Jin W, Xu P, Zhan Y, et al. (2007). Degradable cisplatin-releasing core-shell nanogels from zwitterionic poly(beta -aminoester)-graft-PEG for cancer chemotherapy. Drug Deliv 14:279–86
   PubMed Web of Science ®Google Scholar
• Le Broc-Ryckewaert D, Carpentier R, Lipka E, et al. (2013). Development of innovative paclitaxel-loaded small PLGA nanoparticles: study of their antiproliferative activity and their molecular interactions on prostatic cancer cells. Int J Pharm 454:712–19
   PubMed Web of Science ®Google Scholar
• Lheureux S, Karakasis K, Kohn EC, et al. (2015). Ovarian cancer treatment: the end of empiricism? Cancer 2015;121:3203–11
   PubMed Web of Science ®Google Scholar
• Liang D, Wang AT, Yang ZZ, et al. (2015). Enhance cancer cell recognition and overcome drug resistance using hyaluronic acid and α-tocopheryl succinate based multifunctional nanoparticles. Mol Pharm 12:2189–202
   PubMed Web of Science ®Google Scholar
• Liu D, Liu F, Liu Z, et al. (2011). Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol Pharm 8:2291–301
   PubMed Web of Science ®Google Scholar
• Liu Y, Sun J, Lian H, et al. (2014). Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution. J Pharm Sci 103:1538–47
   PubMed Web of Science ®Google Scholar
• Lopez J, Banerjee S, Kaye SB. (2013). New developments in the treatment of ovarian cancer – future perspectives. Ann Oncol 24 Suppl 10:x69–76
   Google Scholar
• Markman M. (2008). Pharmaceutical management of ovarian cancer: current status. Drugs 68:771–89
   PubMed Web of Science ®Google Scholar
• Nandini PT, Doijad RC, Shivakumar HN. (2015). Formulation and evaluation of gemcitabine-loaded solid lipid nanoparticles. Drug Deliv 22:647–51
   PubMed Web of Science ®Google Scholar
• Saadat E, Amini M, Khoshayand MR, et al. (2014). Synthesis and optimization of a novel polymeric micelle based on hyaluronic acid and phospholipids for delivery of paclitaxel, in vitro and in-vivo evaluation. Int J Pharm 475:163–73
   PubMed Web of Science ®Google Scholar
• Sarisozen C, Vural I, Levchenko T, et al. (2012). Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance. Drug Deliv 19:363–70
   PubMed Web of Science ®Google Scholar
• Shi J, Zhou Z, Di W, et al. (2013). Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer 13:182
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. (2014). Cancer statistics, 2014. CA Cancer J Clin 64:9–29
   PubMed Web of Science ®Google Scholar
• Xu X, Zhao C, Yang H, et al. (2009). Anti-inflammatory activity of injectable dexamethasone acetate-loaded nanostructured lipid carriers. Drug Deliv 18:485–92
   Web of Science ®Google Scholar
• Yang X, Iyer AK, Singh A, et al. (2015). MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Sci Rep 5:8509
   PubMed Web of Science ®Google Scholar
• Yang XY, Li YX, Li M, et al. (2013). Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 334:338–45
   PubMed Web of Science ®Google Scholar
• Yim H, Na K. (2010). Polycationic nanodrug covered with hyaluronic acid for treatment of P-glycoprotein overexpressing cancer cells. Biomacromolecules 11:2387–93
   PubMed Web of Science ®Google Scholar
• Zahedi P, Yoganathan R, Piquette-Miller M, et al. (2012). Recent advances in drug delivery strategies for treatment of ovarian cancer. Expert Opin Drug Deliv 9:567–83
   PubMed Web of Science ®Google Scholar
• Zhang G, Liu F, Jia E, et al. (2015a). Folate-modified, cisplatin-loaded lipid carriers for cervical cancer chemotherapy. Drug Deliv Jul 13:1–5. [Epub ahead of print]. DOI: 10.3109/10717544.2015.1054052
   Web of Science ®Google Scholar
• Zhang W, Li C, Shen C, et al. (2015b). Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment. Drug Deliv Jun 9:1–6. [Epub ahead of print]. DOI: 10.3109/10717544.2015.1035466
   Web of Science ®Google Scholar
• Zhang Y, Zhang H, Wu W, et al. (2014). Folate-targeted paclitaxel-conjugated polymeric micelles inhibits pulmonary metastatic hepatoma in experimental murine H22 metastasis models. Int J Nanomedicine 9:2019–30
   PubMed Web of Science ®Google Scholar